Ind-Swift Ltd
Incorporated in 1986, Ind-Swift Ltd deals in manufacturing and exporting of pharmaceutical products
- Market Cap ₹ 118 Cr.
- Current Price ₹ 21.7
- High / Low ₹ 31.2 / 11.7
- Stock P/E 8.27
- Book Value ₹ -128
- Dividend Yield 0.00 %
- ROCE 26.0 %
- ROE %
- Face Value ₹ 2.00
Pros
Cons
- Company has low interest coverage ratio.
- Promoters have pledged 42.8% of their holding.
- Earnings include an other income of Rs.58.0 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 308 | 263 | 270 | 398 | 411 | 502 | |
| 465 | 328 | 262 | 352 | 369 | 454 | |
| Operating Profit | -157 | -65 | 8 | 45 | 42 | 49 |
| OPM % | -51% | -25% | 3% | 11% | 10% | 10% |
| 13 | -246 | -20 | 24 | 72 | 58 | |
| Interest | 19 | 16 | 7 | 57 | 60 | 63 |
| Depreciation | 36 | 36 | 35 | 32 | 29 | 27 |
| Profit before tax | -200 | -363 | -53 | -20 | 26 | 16 |
| Tax % | 0% | 0% | 1% | 2% | 0% | 14% |
| -214 | -373 | -50 | -20 | 26 | 14 | |
| EPS in Rs | -42.42 | -68.81 | -9.31 | -3.70 | 4.81 | 2.63 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 141% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 43% |
| 3 Years: | 63% |
| 1 Year: | 68% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 10 | 11 | 11 | 11 | 11 | 11 |
| Reserves | -270 | -641 | -688 | -731 | -716 | -702 |
| 1,061 | 1,062 | 1,055 | 1,036 | 993 | 1,014 | |
| 254 | 232 | 237 | 316 | 361 | 331 | |
| Total Liabilities | 1,055 | 665 | 615 | 632 | 649 | 654 |
| 374 | 342 | 311 | 236 | 216 | 184 | |
| CWIP | 4 | 2 | 0 | 9 | 30 | 51 |
| Investments | 39 | 39 | 46 | 64 | 54 | 1 |
| 638 | 281 | 258 | 323 | 349 | 418 | |
| Total Assets | 1,055 | 665 | 615 | 632 | 649 | 654 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| -119 | -2 | 7 | 50 | 73 | 15 | |
| 10 | 4 | -6 | -18 | -29 | 77 | |
| 110 | -11 | -6 | -45 | -47 | -42 | |
| Net Cash Flow | 0 | -8 | -5 | -13 | -3 | 50 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 451 | 151 | 113 | 83 | 93 | 111 |
| Inventory Days | 151 | 86 | 108 | 120 | 150 | 83 |
| Days Payable | 290 | 356 | 394 | 353 | 393 | 262 |
| Cash Conversion Cycle | 311 | -119 | -173 | -149 | -150 | -68 |
| Working Capital Days | 409 | -37 | -57 | -69 | -77 | -27 |
| ROCE % | -14% | -4% | 8% | 26% |
Documents
Announcements
- Announcement Under Reg 30 Of Listing Regulations, 2015- Release Of Pledge On Shares 20 Jul
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 20 Jul
-
Announcement Under Regulation 30 Of SEBI Listing Regulations, 2015
10 Jul - Update on sale of Unit IV of the company
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Jul - Certificate under regulation 74(5) of SEBI (DP) Regulations for the quarter ended 30.06.2024.
- Closure of Trading Window 29 Jun
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
-
Financial Year 2008
from bse
Business Overview:[1]
Company has expertise in finished goods dosage, Active Pharmaceutical Ingredients (API’s) and herbal products. Company also diversified into multiple fields viz., Infrastructure, Printing, Packaging & Stationary, Education, and Media Publication with its every unit as an independent profit earning center